NYSE - Nasdaq Real Time Price • USD
Compare
At close: 4:00 PM EDT
After hours: 5:08 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for LLY
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
878.45 - Open
878.00 - Bid 884.02 x 2200
- Ask 888.00 x 900
- Day's Range
876.86 - 892.20 - 52 Week Range
434.34 - 892.20 - Volume
2,503,177 - Avg. Volume
2,590,179 - Market Cap (intraday)
841.118B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
130.92 - EPS (TTM)
6.76 - Earnings Date Aug 8, 2024
- Forward Dividend & Yield 5.20 (0.59%)
- Ex-Dividend Date May 15, 2024
- 1y Target Est
863.79
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
43,000
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about Eli Lilly and Company
Recent News: LLY
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: LLY
Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is
YTD Return
LLY
52.35%
S&P 500
14.75%
1-Year Return
LLY
99.15%
S&P 500
24.12%
3-Year Return
LLY
314.47%
S&P 500
29.58%
5-Year Return
LLY
752.06%
S&P 500
89.58%
Compare To: LLY
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
885.01
+0.75%
Mkt Cap 841.118B
Industry Drug Manufacturers—General
26.98
-2.00%
Mkt Cap 152.885B
Industry Drug Manufacturers—General
169.68
+0.65%
Mkt Cap 299.633B
Industry Drug Manufacturers—General
127.50
-0.94%
Mkt Cap 322.933B
Industry Drug Manufacturers—General
145.95
+0.28%
Mkt Cap 351.255B
Industry Drug Manufacturers—General
40.97
-0.56%
Mkt Cap 83.05B
Industry Drug Manufacturers—General
79.31
-0.35%
Mkt Cap 245.901B
Industry Drug Manufacturers—General
226.46
-2.26%
Mkt Cap 32.972B
Industry Drug Manufacturers—General
303.28
+1.56%
Mkt Cap 162.69B
Industry Drug Manufacturers—General
64.27
-1.21%
Mkt Cap 80.071B
Industry Drug Manufacturers—General
104.93
-0.75%
Mkt Cap 215.215B
Industry Drug Manufacturers—General
Statistics: LLY
Valuation Measures
As of 6/14/2024
Market Cap
834.88B
Enterprise Value
858.51B
Trailing P/E
129.37
Forward P/E
64.10
PEG Ratio (5yr expected)
2.60
Price/Sales (ttm)
22.09
Price/Book (mrq)
65.16
Enterprise Value/Revenue
23.89
Enterprise Value/EBITDA
88.60
Financial Highlights
Profitability and Income Statement
Profit Margin
17.08%
Return on Assets (ttm)
12.60%
Return on Equity (ttm)
50.75%
Revenue (ttm)
35.93B
Net Income Avi to Common (ttm)
6.14B
Diluted EPS (ttm)
6.76
Balance Sheet and Cash Flow
Total Cash (mrq)
2.65B
Total Debt/Equity (mrq)
204.28%
Levered Free Cash Flow (ttm)
-1.23B
Research Analysis: LLY
Company Insights: LLY
Research Reports: LLY
People Also Watch
BMY Bristol-Myers Squibb Company
40.97
-0.56%
MRK Merck & Co., Inc.
127.50
-0.94%
ABT Abbott Laboratories
103.45
-0.22%
AMGN Amgen Inc.
303.28
+1.56%
NVO Novo Nordisk A/S
140.37
-1.49%
JNJ Johnson & Johnson
145.95
+0.28%
ABBV AbbVie Inc.
169.68
+0.65%
PFE Pfizer Inc.
26.98
-2.00%
UNH UnitedHealth Group Incorporated
489.23
-1.17%
AZN AstraZeneca PLC
79.31
-0.35%
GSK GSK plc
40.66
+0.02%
AVGO Broadcom Inc.
1,828.87
+5.41%
NVS Novartis AG
104.93
-0.75%
MDT Medtronic plc
79.95
-1.35%
BIIB Biogen Inc.
226.46
-2.26%
GILD Gilead Sciences, Inc.
64.27
-1.21%